Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 403

1.

The role and utility of faecal markers in inflammatory bowel disease.

Lehmann FS, Burri E, Beglinger C.

Therap Adv Gastroenterol. 2015 Jan;8(1):23-36. doi: 10.1177/1756283X14553384. Review.

2.

Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.

Burri E, Beglinger C, von Felten S, Lehmann FS.

Dig Dis Sci. 2015 Feb;60(2):485-91. doi: 10.1007/s10620-014-3383-0. Epub 2014 Oct 26.

PMID:
25344905
3.

Exercise-induced chest pain: an atypical manifestation of eosinophilic esophagitis.

Kahn J, Bussmann C, Beglinger C, Straumann A, Hruz P.

Am J Med. 2015 Feb;128(2):196-9. doi: 10.1016/j.amjmed.2014.08.007. Epub 2014 Sep 23.

PMID:
25261012
4.

IBD: Faecal calprotectin testing--the need for better standardization.

Burri E, Beglinger C.

Nat Rev Gastroenterol Hepatol. 2014 Oct;11(10):583-4. doi: 10.1038/nrgastro.2014.154. Epub 2014 Sep 9.

PMID:
25201042
5.

Monitoring disease activity and progression in Crohn's disease. A Swiss perspective on the IBD ahead 'optimised monitoring' recommendations.

Sauter B, Beglinger C, Girardin M, Macpherson A, Michetti P, Schoepfer A, Seibold F, Vavricka SR, Rogler G.

Digestion. 2014;89(4):299-309. doi: 10.1159/000360283. Epub 2014 Jul 25.

6.

Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men.

Steinert RE, Schirra J, Meyer-Gerspach AC, Kienle P, Fischer H, Schulte F, Goeke B, Beglinger C.

Am J Clin Nutr. 2014 Aug;100(2):514-23. doi: 10.3945/ajcn.114.083246. Epub 2014 Jun 25.

PMID:
24965303
7.

Effect of a test meal on meal responses of satiation hormones and their association to insulin resistance in obese adolescents.

Beglinger S, Meyer-Gerspach AC, Graf S, Zumsteg U, Drewe J, Beglinger C, Gutzwiller JP.

Obesity (Silver Spring). 2014 Sep;22(9):2047-52. doi: 10.1002/oby.20805. Epub 2014 Jun 13.

PMID:
24930697
8.

The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients.

Protic M, Seibold F, Schoepfer A, Radojicic Z, Juillerat P, Bojic D, Mwinyi J, Mottet C, Jojic N, Beglinger C, Vavricka S, Rogler G, Frei P.

J Crohns Colitis. 2014 Nov 1;8(11):1427-37. doi: 10.1016/j.crohns.2014.05.004. Epub 2014 Jun 5.

PMID:
24908178
9.

Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease.

Mecklenburg I, Reznik D, Fasler-Kan E, Drewe J, Beglinger C, Hruz P; Swiss IBD Cohort Study Group.

J Crohns Colitis. 2014 Nov 1;8(11):1392-7. doi: 10.1016/j.crohns.2014.04.008. Epub 2014 May 11.

PMID:
24825446
10.

Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma.

Lehmann FS, Trapani F, Fueglistaler I, Terracciano LM, von Flüe M, Cathomas G, Zettl A, Benkert P, Oertli D, Beglinger C.

World J Gastroenterol. 2014 May 7;20(17):4994-9. doi: 10.3748/wjg.v20.i17.4994.

11.

Gut sweet taste receptors and their role in metabolism.

Meyer-Gerspach AC, Wölnerhanssen B, Beglinger C.

Front Horm Res. 2014;42:123-33. doi: 10.1159/000358321. Epub 2014 Apr 7. Review.

PMID:
24732930
12.

Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness.

Burri E, Manz M, Schroeder P, Froehlich F, Rossi L, Beglinger C, Lehmann FS.

BMC Gastroenterol. 2014 Mar 29;14:57. doi: 10.1186/1471-230X-14-57.

13.

Green tea extract enhances parieto-frontal connectivity during working memory processing.

Schmidt A, Hammann F, Wölnerhanssen B, Meyer-Gerspach AC, Drewe J, Beglinger C, Borgwardt S.

Psychopharmacology (Berl). 2014 Oct;231(19):3879-88. doi: 10.1007/s00213-014-3526-1. Epub 2014 Mar 19.

14.

Gastric and intestinal satiation in obese and normal weight healthy people.

Meyer-Gerspach AC, Wölnerhanssen B, Beglinger B, Nessenius F, Napitupulu M, Schulte FH, Steinert RE, Beglinger C.

Physiol Behav. 2014 Apr 22;129:265-71. doi: 10.1016/j.physbeh.2014.02.043. Epub 2014 Feb 28.

PMID:
24582673
15.

Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.

Bernsmeier C, Meyer-Gerspach AC, Blaser LS, Jeker L, Steinert RE, Heim MH, Beglinger C.

PLoS One. 2014 Jan 29;9(1):e87488. doi: 10.1371/journal.pone.0087488. eCollection 2014.

16.

The use of fecal calprotectin as a biomarker in gastrointestinal disease.

Burri E, Beglinger C.

Expert Rev Gastroenterol Hepatol. 2014 Feb;8(2):197-210. doi: 10.1586/17474124.2014.869476. Epub 2013 Dec 18. Review.

PMID:
24345070
17.

[Inflammatory bowel disease].

Patuto N, Beglinger C.

Praxis (Bern 1994). 2013 Aug 21;102(17):1046-52. doi: 10.1024/1661-8157/a001380. Review. German.

PMID:
23965717
18.

Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial.

Steinert RE, Peterli R, Keller S, Meyer-Gerspach AC, Drewe J, Peters T, Beglinger C.

Obesity (Silver Spring). 2013 Dec;21(12):E660-8. doi: 10.1002/oby.20522. Epub 2013 Aug 13.

PMID:
23804517
19.

Infliximab in the treatment of Crohn disease and type 1 diabetes.

Timper K, Hruz P, Beglinger C, Donath MY.

Diabetes Care. 2013 Jul;36(7):e90-1. doi: 10.2337/dc13-0199. No abstract available.

20.

Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans.

Meyer-Gerspach AC, Steinert RE, Keller S, Malarski A, Schulte FH, Beglinger C.

J Clin Endocrinol Metab. 2013 Aug;98(8):3351-8. doi: 10.1210/jc.2012-4109. Epub 2013 Jun 19.

PMID:
23783097
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk